82 related articles for article (PubMed ID: 30370627)
1. Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis.
Konuma T; Shimomura Y; Ozawa Y; Ueda Y; Uchida N; Onizuka M; Akiyama M; Mori T; Nakamae H; Ohno Y; Shiratori S; Onishi Y; Kanda Y; Fukuda T; Atsuta Y; Ishiyama K;
Hematol Oncol; 2019 Feb; 37(1):85-95. PubMed ID: 30370627
[TBL] [Abstract][Full Text] [Related]
2. Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective Trial.
Woo J; Deeg HJ; Storer B; Yeung C; Fang M; Mielcarek M; Scott BL
Biol Blood Marrow Transplant; 2017 Jan; 23(1):176-179. PubMed ID: 27789363
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation.
Oran B; Kongtim P; Popat U; de Lima M; Jabbour E; Lu X; Chen J; Rondon G; Kebriaei P; Ahmed S; Andersson B; Alousi A; Ciurea S; Shpall E; Champlin RE
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1618-25. PubMed ID: 24953017
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies.
Pasquini MC; Zhang MJ; Medeiros BC; Armand P; Hu ZH; Nishihori T; Aljurf MD; Akpek G; Cahn JY; Cairo MS; Cerny J; Copelan EA; Deol A; Freytes CO; Gale RP; Ganguly S; George B; Gupta V; Hale GA; Kamble RT; Klumpp TR; Lazarus HM; Luger SM; Liesveld JL; Litzow MR; Marks DI; Martino R; Norkin M; Olsson RF; Oran B; Pawarode A; Pulsipher MA; Ramanathan M; Reshef R; Saad AA; Saber W; Savani BN; Schouten HC; Ringdén O; Tallman MS; Uy GL; Wood WA; Wirk B; Pérez WS; Batiwalla M; Weisdorf DJ
Biol Blood Marrow Transplant; 2016 Feb; 22(2):248-257. PubMed ID: 26327629
[TBL] [Abstract][Full Text] [Related]
5. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.
Nakamura R; Saber W; Martens MJ; Ramirez A; Scott B; Oran B; Leifer E; Tamari R; Mishra A; Maziarz RT; McGuirk J; Westervelt P; Vasu S; Patnaik M; Kamble R; Forman SJ; Sekeres MA; Appelbaum F; Mendizabal A; Logan B; Horowitz M; Cutler C
J Clin Oncol; 2021 Oct; 39(30):3328-3339. PubMed ID: 34106753
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic cell transplantation (HCT) in MDS patients of older age.
Niederwieser C; Kröger N
Leuk Lymphoma; 2024 May; 65(5):570-584. PubMed ID: 38315612
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102.
Saber W; Bansal A; Li L; Scott BL; Sangaralingham LR; Thao V; Roth JA; Wright W; Steuten LMG; Pidala JA; Mishra A; Maziarz RT; Westervelt P; McGuirk JP; Cutler C; Nakamura R; Ramsey SD
JCO Oncol Pract; 2024 Apr; 20(4):572-580. PubMed ID: 38261970
[TBL] [Abstract][Full Text] [Related]
8. Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML.
Nawas MT; Kosuri S
Blood Adv; 2024 Feb; 8(3):553-561. PubMed ID: 38096805
[TBL] [Abstract][Full Text] [Related]
9. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome.
Scott BL; Wells DA; Loken MR; Myerson D; Leisenring WM; Deeg HJ
Blood; 2008 Oct; 112(7):2681-6. PubMed ID: 18606877
[TBL] [Abstract][Full Text] [Related]
10. Proteomics to predict relapse in patients with myelodysplastic neoplasms undergoing allogeneic hematopoietic cell transplantation.
Guru Murthy GS; Zhang T; Bolon YT; Spellman S; Dong J; Auer P; Saber W
Biomark Res; 2024 Jan; 12(1):10. PubMed ID: 38273355
[TBL] [Abstract][Full Text] [Related]
11. Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.
Maze D; Arcasoy MO; Henrie R; Cerquozzi S; Kamble R; Al-Hadidi S; Yacoub A; Singh AK; Elsawy M; Sirhan S; Smith E; Marcoux C; Viswabandya A; Daly A; Sibai H; McNamara C; Shi Y; Xu W; Lajkosz K; Foltz L; Gupta V
Bone Marrow Transplant; 2024 Feb; 59(2):196-202. PubMed ID: 37938736
[TBL] [Abstract][Full Text] [Related]
12. Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantation.
Wachter F; Pikman Y; Bledsoe J; Kapadia M; Baumeister S; Rowe J; Shimamura A; Place AE; Prockop S; Whangbo J; Lehmann L; Horan J; Pollard J
Clin Case Rep; 2023 Nov; 11(11):e8190. PubMed ID: 38028059
[TBL] [Abstract][Full Text] [Related]
13. Correction: Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.
Maze D; Arcasoy MO; Henrie R; Cerquozzi S; Kamble R; Al-Hadidi S; Yacoub A; Singh AK; Elsawy M; Sirhan S; Smith E; Marcoux C; Viswabandya A; Daly A; Sibai H; McNamara C; Shi Y; Xu W; Lajkosz K; Foltz L; Gupta V
Bone Marrow Transplant; 2024 Feb; 59(2):295. PubMed ID: 38279008
[No Abstract] [Full Text] [Related]
14. Effect of bone marrow CD34+cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation.
Patel SS; Rybicki LA; Corrigan D; Dumont C; Bolwell B; Dean R; Figueroa P; Hanna R; Liu H; Gerds AT; Hill B; Jagadeesh D; Kalaycio M; Pohlman B; Ricci K; Sobecks R; Lu W; Hamilton BK; Majhail NS
Bone Marrow Transplant; 2019 May; 54(5):775-781. PubMed ID: 30375493
[TBL] [Abstract][Full Text] [Related]
15. Upfront allogeneic hematopoietic cell transplantation (HCT) versus remission induction chemotherapy followed by allogeneic HCT for acute myeloid leukemia with multilineage dysplasia: A propensity score matched analysis.
Konuma T; Harada K; Yamasaki S; Mizuno S; Uchida N; Takahashi S; Onizuka M; Nakamae H; Hidaka M; Fukuda T; Ohashi K; Kohno A; Matsushita A; Kanamori H; Ashida T; Kanda J; Atsuta Y; Yano S;
Am J Hematol; 2019 Jan; 94(1):103-110. PubMed ID: 30370944
[TBL] [Abstract][Full Text] [Related]
16. Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasia.
Mashima K; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Umino K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Sugimoto M; Ishihara Y; Ashizawa M; Yamamoto C; Fujiwara SI; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Ann Hematol; 2019 May; 98(5):1127-1133. PubMed ID: 30474718
[TBL] [Abstract][Full Text] [Related]
17. Non-Structural Proteins from Human T-cell Leukemia Virus Type 1 in Cellular Membranes-Mechanisms for Viral Survivability and Proliferation.
Georgieva ER
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30413005
[TBL] [Abstract][Full Text] [Related]
18. A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patients.
Boutault R; Peterlin P; Boubaya M; Sockel K; Chevallier P; Garnier A; Guillaume T; Le Bourgeois A; Debord C; Godon C; Le Bris Y; Theisen O; Kroschinsky F; Moreau P; Béné MC; Platzbecker U; Eveillard M
Br J Haematol; 2018 Dec; 183(5):736-746. PubMed ID: 30406952
[TBL] [Abstract][Full Text] [Related]
19. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials.
Platzbecker U; Fenaux P; Adès L; Giagounidis A; Santini V; van de Loosdrecht AA; Bowen D; de Witte T; Garcia-Manero G; Hellström-Lindberg E; Germing U; Stauder R; Malcovati L; Sekeres MA; Steensma DP; Gloaguen S
Blood; 2019 Mar; 133(10):1020-1030. PubMed ID: 30404811
[TBL] [Abstract][Full Text] [Related]
20. Individual HLAs influence immunological events in allogeneic stem cell transplantation from HLA-identical sibling donors.
Morishima S; Fukuda T; Doki N; Mori T; Onizuka M; Kawakita T; Kato C; Ozawa Y; Tanaka M; Kurokawa M; Kamimura T; Inoue M; Tanaka J; Ichinohe T; Atsuta Y; Morishima Y;
Bone Marrow Transplant; 2021 Mar; 56(3):646-654. PubMed ID: 33037403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
